Ireland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth

Theravance Biopharma

07/05/2026 13:41

Overview

Ireland-based respiratory medicines developer's Q1 revenue beat analyst expectations

Q1 adjusted net income turned positive

Company delivered ~20% yr/yr reduction in operating expenses, restructuring on track

Outlook

Theravance expects full run-rate cost savings of $70 mln to materialize in Q3 2026

Company projects annualized cash flow of $60-$70 mln starting in Q3 2026

Theravance expects operating expenses to decrease by about 60% versus 2025 actuals

Result Drivers

YUPELRI SALES GROWTH - Q1 Viatris collaboration revenue rose 15% yr/yr, driven by higher YUPELRI net sales and improved net pricing

COST REDUCTION - Operating expenses fell ~20% yr/yr in Q1, reflecting restructuring and wind-down of R&D activities

Company press release: ID:nPn7ThZtLa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$17.70 mln
$17.20 mln (4 Analysts)
Q1 Adjusted Net Income
$639,000


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Theravance Biopharma Inc is $17.00, about 0.4% above its May 6 closing price of $16.94

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)